A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

Palbociclib is a CDK4/6 inhibitor that received FDA approval for treatment of hormone receptor positive (HR+) HER2 negative (HER2neg) advanced breast cancer. To better personalize patients treatment it is critical to identify subgroups that would mostly benefit from it. We hypothesize that complex a...

Descripción completa

Detalles Bibliográficos
Autores principales: Malorni, Luca, Piazza, Silvano, Ciani, Yari, Guarducci, Cristina, Bonechi, Martina, Biagioni, Chiara, Hart, Christopher D., Verardo, Roberto, Leo, Angelo Di, Migliaccio, Ilenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356535/
https://www.ncbi.nlm.nih.gov/pubmed/27634906
http://dx.doi.org/10.18632/oncotarget.12010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356535/
https://www.ncbi.nlm.nih.gov/pubmed/27634906
http://dx.doi.org/10.18632/oncotarget.12010

Ejemplares similares